Best High-Yield Dividend Stocks to Watch in 2026: Realty Income, Verizon, and Pfizer

TLDR

• Realty Income yields above 5% and has raised its dividend over 120 times since listing
• Verizon has grown its dividend annually for nearly two decades and is a top high-yield blue-chip
• Pfizer’s yield has risen as its share price pulled back following the drop in COVID revenue

---

Three dividend stocks are standing out for income investors in 2026. Each one offers a different approach to generating reliable returns.

Realty Income: Monthly Payouts and a 5% Yield

Realty Income has built its entire identity around income. The company owns thousands of commercial properties leased to major tenants under long-term contracts.

Realty Income Corporation, O

It has raised its dividend more than 120 times since going public and currently yields above 5%. Its portfolio covers retail, industrial, and gaming properties, spreading risk across multiple sectors.

The stock pays monthly, which sets it apart from most dividend stocks that pay quarterly. For investors who want regular income, that cadence is a draw.

Analyst consensus sits at 7 Buy, 7 Hold, and 1 Sell, with an average price target of around $67.35.

Verizon: Steady Income From a Telecom Giant

Verizon has raised its dividend every year for close to two decades. The company’s wireless and broadband services generate steady cash flow, and its customer base is large.

Verizon Communications Inc., VZ

Growth has been slow, but the services it provides are essential. That makes the revenue stream relatively predictable compared to more cyclical businesses.

The stock remains one of the highest-yielding large-cap names in the U.S. market. Investors tend to choose it for income and lower price swings rather than capital gains.

For investors who want a defensive income stock with a long track record, Verizon fits that role.

Pfizer: A High Yield With a Recovery Angle

Pfizer’s share price pulled back after COVID vaccine revenue declined sharply. That drop pushed the dividend yield higher, which has attracted income-focused investors.

Pfizer Inc., PFE

The company still has a broad drug pipeline and continues investing in research and development. Newer products in its portfolio are being watched to see if they can replace the revenue lost from pandemic-related sales.

Pfizer still carries a wide analyst following and has not cut its dividend despite the revenue slowdown. That has kept it on the watchlist for investors willing to take on some uncertainty.

Investors with patience may benefit if the newer drugs gain traction over the next few years.